Patients taking angiotensin-converting enzyme inhibitors/angiotensin II type I receptor blockers: higher risks of severe acute respiratory syndrome coronavirus 2 infection but milder clinical manifestations?

Chin Med J (Engl). 2020 Nov 20;133(22):2650-2652. doi: 10.1097/CM9.0000000000000996.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / adverse effects*
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / etiology*
  • Humans
  • Pandemics
  • Peptidyl-Dipeptidase A / physiology
  • Pneumonia, Viral / etiology*
  • SARS-CoV-2

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2